All data that were collected with the MDS-ABI as part of studies among persons with brain injury, executed by the Limburg Brain Injury Center (EHL) up until the date of publication.

Data with study code F: data from feasibility study of the MDS-ABI (https://doi.org/10.1371/journal.pone.0235085)

Sampling setting: healthcare institutions for patients with ABI. Inclusion criteria: adults with medically confirmed ABI who were capable of providing informed consent. Exclusion criteria: Progressive neurological conditions such as Parkinson's or Alzheimer's disease. Sample size: 50 Administered parts: Part A: administered without screening question for comorbidity (unavailable) Part B: administered Part C: not administered (unavailable at the time) Part D: not administered (unavailable at the time)

Data with study code D: cross-sectional study into characteristics of patients with ABI in The Netherlands (https://doi.org/10.1080/09602011.2022.2149559)

Sampling setting: community and healthcare institutions for patients with ABI. Inclusion criteria: adults with medically confirmed ABI who were capable of providing informed consent. Exclusion criteria: Progressive neurological conditions such as Parkinson's or Alzheimer's disease. Sample size: 73 Administered parts: Part A: administered without screening question for comorbidity (unavailable) Part B: administered Part C: administered when possible (caregiver present or healthcare professional who knew the patient well) Part D: administered when possible (caregiver present)

Data with study code sTBI: long-term follow-up study into critically ill TBI patients (https://doi.org/10.1089/neu.2022.0474).

Sampling setting: community and residential institutions for patients with ABI. Inclusion criteria: TBI patients were eligible for participation if they had been admitted to the ICU of Maastricht University Medical Center+ (MUMC+), an academic teaching hospital and neurosurgical referral center, between 6 months and 5 years prior to the screening date. Exclusion criteria: Progressive neurological conditions such as Parkinson's or Alzheimer's disease. Sample size: 52 Administered parts: Part A: administered without screening question for comorbidity (unavailable) Part B: administered Part C: administered when possible (caregiver present or healthcare professional who knew the patient well) Part D: administered when possible (caregiver present)